Labeler
Qilu Pharmaceutical Co., Ltd. NDC Codes
Qilu Pharmaceutical Co., Ltd. lists 54 finished drug products in the FDA NDC Directory under NDC labeler code 67184.
Overview
Each product below links to its own NDC page with package NDCs in 10- and 11-digit form.
- Drugs
- Olanzapine, Oxaliplatin, Tadalafil, Ceftriaxone Sodium, Irinotecan Hydrochloride, Cefepime, Micafungin, Bumetanide, Amikacin Sulfate, imatinib mesylate, Pemetrexed, Palonosetron, Nicardipine Hydrochloride, Mirabegron, Mirabgeorn
- Active ingredients
- Olanzapine, Oxaliplatin, Tadalafil, Ceftriaxone sodium, Irinotecan hydrochloride, Cefepime hydrochloride, Mirabegron, Micafungin, Bumetanide, Amikacin sulfate, Imatinib mesylate, Pemetrexed disodium hemipentahydrate
- NDC labeler codes
- 67184
- Strengths
- Irinotecan hydrochloride 20 mg/mL; Bumetanide .25 mg/mL; Amikacin sulfate 250 mg/mL; Oxaliplatin 50 mg/10mL; Oxaliplatin 100 mg/20mL; Olanzapine 10 mg/2mL; Nicardipine hydrochloride 2.5 mg/mL; Mirabegron 25 mg/1; Mirabegron 50 mg/1; Ganirelix acetate 250 ug/.5mL; Micafungin 10 mg/mL; Micafungin 20 mg/mL; Icosapent ethyl 1 g/1; Hydroxyurea 500 mg/1; Gefitinib 250 mg/1; Imatinib mesylate 100 mg/1; Imatinib mesylate 400 mg/1; Pemetrexed disodium hemipentahydrate 100 mg/4mL; Pemetrexed disodium hemipentahydrate 500 mg/20mL; Bortezomib 3.5 mg/1
- Dosage forms
- Injection, Solution, Injection, Powder, Lyophilized, For solution, Injection, Powder, For solution, Tablet, Tablet, Film coated, Injection, Tablet, Film coated, Extended release, Capsule, Kit, Tablet, Coated
- Routes
- Intravenous, Oral, Intramuscular, Subcutaneous
- Drug classes (FDA established)
- Cephalosporin Antibacterial, Atypical Antipsychotic, Platinum-based Drug, Phosphodiesterase 5 Inhibitor, Kinase Inhibitor, Serotonin-3 Receptor Antagonist, Topoisomerase Inhibitor, beta3-Adrenergic Agonist, Echinocandin Antifungal, Loop Diuretic, Aminoglycoside Antibacterial, Folate Analog Metabolic Inhibitor, Dihydropyridine Calcium Channel Blocker, Gonadotropin Releasing Hormone Receptor Antagonist, Antimetabolite, Proteasome Inhibitor, Lipopeptide Antibacterial, Nucleoside Metabolic Inhibitor, Substance P/Neurokinin-1 Receptor Antagonist, Cholinergic Muscarinic Antagonist
- HCPCS / J-code
- J0696 — Injection, ceftriaxone sodium, per 250 mg, J2405 — Injection, ondansetron hydrochloride, per 1 mg
- Package NDCs
- 65
NDC codes
Newest listings first. Each row links to the product’s NDC page.
| Product | Strength | Form · route | Product NDC | Package NDCs (11-digit) | HCPCS |
|---|---|---|---|---|---|
| Olanzapine | Olanzapine 10 mg/2mL | Injection, Powder, For solutionIntramuscular | 67184-0573 | 67184-0573-01 | — |
| Nicardipine Hydrochloride | Nicardipine hydrochloride 2.5 mg/mL | Injection, SolutionIntravenous | 67184-0611 | 67184-0611-02 | — |
| Mirabegron | Mirabegron 25 mg/1 | Tablet, Film coated, Extended releaseOral | 67184-0571 | 67184-0571-0167184-0571-02 | — |
| Mirabgeornmirabegron | Mirabegron 50 mg/1 | Tablet, Film coated, Extended releaseOral | 67184-0572 | 67184-0572-0167184-0572-02 | — |
| Ganirelix Acetate | Ganirelix acetate 250 ug/.5mL | Injection, SolutionSubcutaneous | 67184-0574 | 67184-0574-01 | — |
| Micafungin | Micafungin 10 mg/mL | Injection, Powder, Lyophilized, For solutionIntravenous | 67184-0589 | 67184-0589-0167184-0589-02 | — |
| Micafungin | Micafungin 20 mg/mL | Injection, Powder, Lyophilized, For solutionIntravenous | 67184-0590 | 67184-0590-0167184-0590-02 | — |
| Icosapent Ethyl | Icosapent ethyl 1 g/1 | CapsuleOral | 67184-0582 | 67184-0582-01 | — |
| Bumetanide | Bumetanide .25 mg/mL | InjectionIntramuscular, Intravenous | 67184-0593 | 67184-0593-02 | — |
| Bumetanide | Bumetanide .25 mg/mL | InjectionIntramuscular, Intravenous | 67184-0594 | 67184-0594-02 | — |
| Cetrorelix acetatecetrorelix acetate for injection | — | KitSubcutaneous | 67184-0605 | 67184-0605-02 | — |
| Amikacin Sulfate | Amikacin sulfate 250 mg/mL | Injection, SolutionIntramuscular, Intravenous | 67184-0569 | 67184-0569-02 | — |
| Amikacin Sulfate | Amikacin sulfate 250 mg/mL | Injection, SolutionIntramuscular, Intravenous | 67184-0570 | 67184-0570-02 | — |
| Hydroxyurea | Hydroxyurea 500 mg/1 | CapsuleOral | 67184-0607 | 67184-0607-01 | — |
| Melphalan Hydrochloride | — | KitIntravenous | 67184-0618 | 67184-0618-02 | — |
| Gefitinib | Gefitinib 250 mg/1 | Tablet, CoatedOral | 67184-0531 | 67184-0531-0167184-0531-0267184-0531-03 | — |
| imatinib mesylate | Imatinib mesylate 100 mg/1 | TabletOral | 67184-0532 | 67184-0532-0167184-0532-0267184-0532-03 | — |
| imatinib mesylate | Imatinib mesylate 400 mg/1 | TabletOral | 67184-0533 | 67184-0533-0167184-0533-0267184-0533-03 | — |
| Pemetrexedpemetrexed disodium | Pemetrexed disodium hemipentahydrate 100 mg/4mL | Injection, Powder, Lyophilized, For solutionIntravenous | 67184-0503 | 67184-0503-01 | — |
| Pemetrexedpemetrexed disodium | Pemetrexed disodium hemipentahydrate 500 mg/20mL | Injection, Powder, Lyophilized, For solutionIntravenous | 67184-0504 | 67184-0504-01 | — |
| Bortezomib | Bortezomib 3.5 mg/1 | Injection, Powder, Lyophilized, For solutionIntravenous, Subcutaneous | 67184-0530 | — | — |
| Tadalafil | Tadalafil 5 mg/1 | Tablet, Film coatedOral | 67184-0524 | 67184-0524-0167184-0524-02 | — |
| Tadalafil | Tadalafil 10 mg/1 | Tablet, Film coatedOral | 67184-0525 | 67184-0525-02 | — |
| Tadalafil | Tadalafil 20 mg/1 | Tablet, Film coatedOral | 67184-0526 | 67184-0526-0167184-0526-02 | — |
| Tadalafil | Tadalafil 2.5 mg/1 | Tablet, Film coatedOral | 67184-0523 | 67184-0523-0167184-0523-02 | — |
| Daptomycin | Daptomycin 500 mg/10mL | Injection, Powder, Lyophilized, For solutionIntravenous | 67184-0549 | 67184-0549-01 | — |
| Decitabine | Decitabine 50 mg/20mL | Injection, Powder, Lyophilized, For solutionIntravenous | 67184-0535 | 67184-0535-01 | — |
| Fosaprepitant Dimeglumine | Fosaprepitant dimeglumine 150 mg/5mL | Injection, Powder, Lyophilized, For solutionIntravenous | 67184-0540 | 67184-0540-01 | — |
| Solifenacin Succinatesolifenacin succinate tablets | Solifenacin succinate 10 mg/1 | Tablet, Film coatedOral | 67184-0517 | 67184-0517-0167184-0517-0267184-0517-03+1 more | — |
| Palonosetronpalonosetron hydrochloride | Palonosetron hydrochloride .25 mg/5mL | InjectionIntravenous | 67184-0514 | 67184-0514-01 | — |
| Palonosetronpalonosetron hydrochloride | Palonosetron hydrochloride .075 mg/1.5mL | InjectionIntravenous | 67184-0515 | 67184-0515-02 | — |
| Ceftriaxone Sodium | Ceftriaxone sodium 250 mg/1 | Injection, Powder, For solutionIntramuscular, Intravenous | 67184-1005 | 67184-1005-0167184-1005-02 | J0696 |
| Ceftriaxone Sodium | Ceftriaxone sodium 500 mg/1 | Injection, Powder, For solutionIntramuscular, Intravenous | 67184-1006 | 67184-1006-0167184-1006-02 | J0696 |
| Ceftriaxone Sodium | Ceftriaxone sodium 1 g/1 | Injection, Powder, For solutionIntramuscular, Intravenous | 67184-1007 | 67184-1007-01 | J0696 |
| Ceftriaxone Sodium | Ceftriaxone sodium 2 g/1 | Injection, Powder, For solutionIntramuscular, Intravenous | 67184-1008 | 67184-1008-01 | J0696 |
| Oxaliplatin | Oxaliplatin 50 mg/10mL | Injection, SolutionIntravenous | 67184-0508 | 67184-0508-01 | — |
| Oxaliplatin | Oxaliplatin 100 mg/20mL | Injection, SolutionIntravenous | 67184-0509 | 67184-0509-01 | — |
| Oxaliplatin | Oxaliplatin 200 mg/40mL | Injection, SolutionIntravenous | 67184-0510 | 67184-0510-01 | — |
| Oxaliplatin | Oxaliplatin 50 mg/10mL | Injection, Powder, Lyophilized, For solutionIntravenous | 67184-0501 | 67184-0501-01 | — |
| Oxaliplatin | Oxaliplatin 100 mg/20mL | Injection, Powder, Lyophilized, For solutionIntravenous | 67184-0502 | 67184-0502-01 | — |
| Irinotecan Hydrochloride | Irinotecan hydrochloride 20 mg/mL | Injection, SolutionIntravenous | 67184-0511 | 67184-0511-01 | — |
| Irinotecan Hydrochloride | Irinotecan hydrochloride 20 mg/mL | Injection, SolutionIntravenous | 67184-0512 | 67184-0512-01 | — |
| Irinotecan Hydrochloride | Irinotecan hydrochloride 20 mg/mL | Injection, SolutionIntravenous | 67184-0513 | 67184-0513-01 | — |
| Cefepimecefepime hydrochloride | Cefepime hydrochloride 500 mg/1 | Injection, Powder, For solutionIntramuscular, Intravenous | 67184-1002 | 67184-1002-01 | — |
| Cefepimecefepime hydrochloride | Cefepime hydrochloride 1 g/1 | Injection, Powder, For solutionIntramuscular, Intravenous | 67184-1003 | 67184-1003-01 | — |
| Cefepimecefepime hydrochloride | Cefepime hydrochloride 2 g/1 | Injection, Powder, For solutionIntravenous | 67184-1004 | 67184-1004-01 | — |
| Olanzapine | Olanzapine 2.5 mg/1 | TabletOral | 67184-0561 | — | — |
| Olanzapine | Olanzapine 5 mg/1 | TabletOral | 67184-0562 | — | — |
| Olanzapine | Olanzapine 7.5 mg/1 | TabletOral | 67184-0563 | — | — |
| Olanzapine | Olanzapine 10 mg/1 | TabletOral | 67184-0564 | — | — |
Qilu Pharmaceutical Co., Ltd.: common questions
- What is Qilu Pharmaceutical Co., Ltd.'s NDC labeler code?
- 67184. The labeler code is the first segment of each NDC. About labeler codes.
- Is there a J-code for Qilu Pharmaceutical Co., Ltd.?
- Med-Code's HCPCS directory matches J0696, J2405 to these products. NDC vs J-code.
- Which NDC goes on a claim?
- The package NDC of what was given, in 11-digit form. How to convert a 10-digit NDC.